Over 30 years of clinical trials in humans have proven that interventions to raise circulating IGF1 do NOT improve muscle quality, strength, or functional capacity in older adults.
Across all these trials, a striking pattern emerges: while raising systemic IGF-1 levels by +50 to +130 ng/mL reliably increases lean body mass (fat-free mass), it almost universally fails to improve muscle strength or physical function in older adults.
The consensus across 30+ years of clinical trials is that increasing systemic IGF-1 expands extracellular fluid and non-contractile lean mass without improving contractile muscle quality, strength, or functional capacity in older adults.
Key Studies Elevating IGF-1 & Testing Muscle Outcomes
(See References section at the end of the post.)
- Oral Growth Hormone
Secretagogues (MK-677 / Ibutamoren)
Chapman et al. (1996):
Evaluated daily oral administration of MK-677 (25 mg/day) in 32 healthy older adults (aged 64–81).
- IGF-1 Increase: Serum IGF-1 rose from a baseline of 141 ng/mL to 219 ng/mL at 2 weeks and 265 ng/mL at 4 weeks—an average increase of +124 ng/mL (Chapman et al., 1996).
- Muscle Impact: Restored IGF-1 levels to those of healthy young adults and laid the groundwork for longer-term composition trials. While this initial study demonstrated that acute IGF-1 elevation promotes systemic protein accretion (a key metabolic driver for skeletal muscle preservation), it was intentionally short-term, serving as the proof-of-concept that led to longer-term trials (such as Nass et al., 2008) which subsequently confirmed that this nitrogen-sparing effect increases total fat-free mass without yielding accompanying gains in functional muscle strength.
Nass et al. (2008):
A 2-year randomized, double-blind, placebo-controlled trial of 25 mg daily MK-677 in healthy older adults (aged 60–81).
- IGF-1 Increase: Maintained a sustained increase in serum IGF-1 of +70 to +100 ng/mL over 12 months.
- Muscle Impact: Significantly increased fat-free mass +1.1 kg and appendicular lean mass relative to placebo. However, the study showed no significant improvements in muscle strength (e.g., leg press, chest press) or physical performance measures (e.g., gait speed, stair climb).
- Ghrelin Receptor Agonists (Anamorelin)
Dawson-Hughes et al. (2023):
Tested the ghrelin receptor agonist anamorelin in older adults with osteosarcopenia.
- IGF-1 Increase: Mean serum IGF-1 reached 162 ng/mL, representing an increase of >50 ng/mL over baseline levels (Dawson-Hughes et al., 2023).
- Muscle Impact: Successfully increased lean body mass, but did not translate into gains in muscle strength or lower-extremity physical function.
- Recombinant Human Growth Hormone (rhGH) Injections
Several landmark trials in the 1990s and early 2000s directly administered rhGH to healthy older adults:
Rudman et al. (1990) & Papadakis et al. (1996):
In healthy men over 60–70 years old with low baseline IGF-1 <110 ng/mL, 6 months of rhGH therapy raised mean serum IGF-1 from 105 ng/mL to 230 ng/mL (an increase of +125 ng/mL).
- Muscle Impact: Lean tissue mass increased by 4% to 8%, but measured isometric and isotonic muscle strength (knee extension/flexion, handgrip) showed no difference compared to controls.
Blackman et al. (2002):
A 26-week trial combining rhGH with or without sex steroid replacement in adults aged 65–88.
- IGF-1 Increase: Elevated IGF-1 by +96 to +138 ng/mL in GH-treated groups.
- Muscle Impact: Lean body mass increased (1.0 to 3.1kg), but strength and VO2-max gains were negligible compared to control groups.
Summary Takeaway
If the goal is to significantly increase circulating IGF-1, the GH secretagogues (MK-677, capromorelin) and rhGH reliably achieve this by margins of 50 to 130 ng/mL.
However, the consensus across 30+ years of clinical trials is that increasing systemic IGF-1 expands extracellular fluid and non-contractile lean mass without improving contractile muscle quality, strength, or functional capacity in older adults.
References
Arnarson, A., Geirsdottir, O. G., Ramel, A., Jonsson, P. V., & Thorsdottir, I. (2015). Insulin-like growth factor-1 and resistance exercise in community dwelling old adults. The Journal of Nutrition, Health & Aging, 19(8), 856–860. Insulin-Like Growth Factor-1 and Resistance Exercise in Community Dwelling Old Adults. (J Nutr Health Aging, 2015)
Cited by: 55
Chapman, I. M., Bach, M. A., Van Cauter, E., Farmer, M., Krupa, D., Taylor, A. M., Schilling, L. M., Cole, K. Y., Skiles, E. H., Pezzoli, S. S., Hartman, M. L., Veldhuis, J. D., Gormley, G. J., & Thorner, M. O. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. The Journal of Clinical Endocrinology & Metabolism, 81(12), 4249–4257. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral… (J Clin Endocrinol Metab, 1996)
Cited by: 346
Dawson-Hughes, B., Barger, K., Reitshamer, E., Fielding, R. A., Evans, W., & Ceglia, L. (2023). Effect of Anamorelin, a Ghrelin Receptor Agonist, on Muscle and Bone in Adults With Osteosarcopenia. The Journal of Clinical Endocrinology & Metabolism, 109(3), e945–e955. Effect of Anamorelin, a Ghrelin Receptor Agonist, on Muscle and Bone in Adults With… (The Journal of Clinical Endocrinology & Metabolism, 2024)
Cited by: 6
This post was written in collaboration with Gemeni AI.
#igf1HD #muscleHD #growthhormoneHD #sarcopeniaHD #elderlyHD #peptidesHD


